SPARC
Sun Pharma Advanced Research Co. Ltd.
Each stock's 10,000-path forecast, rendered as light.
Sun Pharma Advanced Research Co. Ltd. (SPARC) Stock Analysis & Case Study
Is SPARC a good buy? The data-driven verdict.
Sun Pharma Advanced Research Co. Ltd. (SPARC) trades at ₹213,on the numbers it screens attractive, a Downstox Snapshot Score of 71/100.
On the numbers, Sun Pharma Advanced Research Co. Ltd. (SPARC) screens attractive, a Downstox Snapshot Score of 71/100, weighing inexpensive at 4.4× earnings, ROE of 279.0%, a 48% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
SPARC fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How SPARC ranks against the 2,373 companies in our screener
- SPARC's market cap of 6,919 Cr ranks in the 70th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SPARC's book value of ₹41 ranks in the 29th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SPARC's promoter holding of 65.7% ranks in the 64th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SPARC's 3-year profit (PAT) growth of 108.0% ranks in the top 5% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SPARC's 3-year revenue growth of 99.0% ranks in the top 3% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SPARC's debt-to-equity ratio of 0.42x is lower than 41% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is SPARC overvalued? SPARC P/E vs peers
SPARC trades at 4.4× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
SPARC share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of SPARC history (-6%/yr drift, 51%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| SPARC 2027 | ₹108 | ₹207 | ₹397 | -3% |
| SPARC 2028 | ₹81 | ₹201 | ₹503 | -6% |
| SPARC 2029 | ₹64 | ₹196 | ₹597 | -8% |
| SPARC 2030 | ₹54 | ₹190 | ₹677 | -11% |
| SPARC 2031 | ₹44 | ₹185 | ₹775 | -13% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability SPARC goes up, or doubles?
The bull case for SPARC
- SPARC's P/E of 4.4x is lower than 95% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SPARC's return on equity of 279.0% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SPARC's return on capital employed of 164.0% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹597.
The bear case & risks
- High historical volatility (51%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹64.
SPARC volatility & expected range, how bumpy is the ride?
Over the last 9.8 years SPARC compounded at -6%/year with annualized volatility of 51%. That volatility implies a 1-year 80% range of ₹108-₹397, the honest backbone behind any single price target.
SPARC price forecast, the full 60-month probability fan
SPARC price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds SPARC hits common targets within the simulated horizon?
Full multi-horizon detail on the SPARC price target & forecast page.
SPARC Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. SPARC scores 5/8, mixed financial health.
SPARC MTF margin & leverage across 7 brokers
Margin Trading Facility lets you buy SPARC with part of the capital. Lower margin % = higher leverage. Rates compared across 7 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Zerodha | 40.89% | 2.4× |
| Groww | 41.05% | 2.4× |
| Kotak NeoCHEAPEST | 40.82% | 2.4× |
| Paytm Money | 100.00% | 1.0× |
| Pocketful | 41.35% | 2.4× |
| Anand Rathi | 100.00% | 1.0× |
| Share India | 40.99% | 2.4× |
Compare every broker on the SPARC MTF page.
About Sun Pharma Advanced Research Co. Ltd.: sector, index & market-cap context
Sun Pharma Advanced Research Co. Ltd. (SPARC) is a small-cap NSE-listed company, with a market capitalisation of ₹6,919 Cr. See more stocks on our screener.
How the SPARC Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Sun Pharma Advanced Research Co. Ltd.'s public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
SPARC analysis, FAQs
Is Sun Pharma Advanced Research Co. Ltd. (SPARC) a good buy?
On the numbers, Sun Pharma Advanced Research Co. Ltd. (SPARC) screens attractive, a Downstox Snapshot Score of 71/100, weighing inexpensive at 4.4× earnings, ROE of 279.0%, a 48% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is SPARC overvalued or undervalued?
SPARC trades at 4.4× earnings, inexpensive versus the ~22× long-run Nifty average.
What is the SPARC share price target for 2031?
SPARC's probability-weighted 2031 median target is ₹185, with an 80% range of ₹44-₹775 (10,000-path Monte-Carlo).
What is the probability SPARC doubles in 5 years?
The modelled probability of SPARC reaching ₹426 (2×) within 5 years is 23%.
What is the bull case for SPARC?
SPARC's P/E of 4.4x is lower than 95% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. SPARC's return on equity of 279.0% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. SPARC's return on capital employed of 164.0% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in SPARC?
High historical volatility (51%/yr) means a wide, bumpy range of outcomes, size positions accordingly.